Cipla is currently trading at Rs. 1178.10, up by 27.95 points or 2.43% from its previous closing of Rs. 1150.15 on the BSE.
The scrip opened at Rs. 1155.55 and has touched a high and low of Rs. 1196.85 and Rs. 1151.00 respectively. So far 45211 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1277.55 on 10-Aug-2023 and a 52 week low of Rs. 852.00 on 22-Mar-2023.
Last one week high and low of the scrip stood at Rs. 1210.30 and Rs. 1132.00 respectively. The current market cap of the company is Rs. 95292.66 crore.
The promoters holding in the company stood at 33.47%, while Institutions and Non-Institutions held 49.85% and 16.67% respectively.
Cipla has reported 42.95% rise in its net profit at Rs 1029.69 crore for the second quarter ended September 30, 2023 (Q2FY24) as compared to Rs 720.30 crore for the same quarter in the previous year. Total income of the company increased by 14.76% at Rs 4869.81 crore for Q2FY24 as compared Rs 4243.55 crore for the corresponding quarter previous year.
On consolidated basis, the company has reported 44.89% rise in its net profit at Rs 1155.37 crore for the quarter under review as compared to Rs 797.41 crore for the same quarter in the previous year. Total income of the company increased by 15.17% at Rs 6854.47 crore for Q2FY24 as compared Rs 5951.49 crore for the corresponding quarter previous year.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: